ArticleThe Laryngoscope2026
Endothelial Hydrogels Improve Microvascular Regeneration and Perfusion in Tracheal Scaffolds.
Article in The Laryngoscope, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Endothelial Hydrogels Improve Microvascular Regeneration and Perfusion in Tracheal Scaffolds.The Laryngoscope · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
objectiveVascularization remains a major barrier to the clinical translation of airway replacement. We previously demonstrated that engineered tracheal scaffolds support neovascularization, although restoration of microvascular perfusion is delayed in part due to a reduction in capillary branching. Endothelial hydrogels (EH) have demonstrated the potential to enhance vascular regeneration in several domains of tissue engineering, yet their application in airway replacement has not been fully evaluated. In this study, we assessed the impact of EH on microvascular regeneration and perfusion in tracheal scaffolds.
methodsTracheal scaffolds were fabricated from C57BL/6J mice. EH were formulated with endothelial cells (EC) from human or mouse lineages and collagen, then applied to tracheal scaffolds. EH-scaffolds were cultured ex vivo for 7 days and stained with CD31, DAPI, lectin-FITC, and vascular endothelial growth factor (VEGF). The optimal EH composition was evaluated in vivo using orthotopic tracheal transplantation. At 1-month, microvascular regeneration was quantified, patterning was assessed via Sholl analysis, and perfusion was quantified using lectin-FITC.
resultsEH supported EC attachment on tracheal scaffolds. The ideal EH composition for maximal EC coverage was 3.6 × 10
conclusionEH enhances microvascular regeneration and perfusion of engineered tracheal scaffolds in vivo, thus supporting the potential of EH as a strategy to accelerate vascular regeneration in airway reconstruction. LEVEL OF EVIDENCE: N/A.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.